November 2, 2011
Daiichi Sankyo announced on October 31 that it had suspended PII clinical trials that had been conducted in the US and Europe for its novel anticoagulant oral Factor Xa inhibitor edoxaban (brand name in Japan: Lixiana) for the prevention of...read more